Form 4: CytomX Therapeutics Officer Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, sold 4,025 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

  • On March 18, 2025, Yu-Waye Chu, the Chief Medical Officer of CytomX Therapeutics, sold 4,025 shares of common stock.
  • The shares were sold at a price of $0.599 per share.
  • The sale was executed to satisfy tax or other government withholding obligations related to the vesting of restricted stock units (RSUs).
  • Following the transaction, Chu still beneficially owns 135,725 shares, which includes 131,000 RSUs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales for tax purposes, indicating a neutral sentiment.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and officers.

Stakeholder Impact

  • The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

DateDescription
03/18/2025Date of stock sale transaction
03/20/2025Date of signature on the Form 4 filing

Keywords

Form 4, CytomX Therapeutics, CTMX, Yu-Waye Chu, Chief Medical Officer, Stock Sale, Restricted Stock Units, Tax Obligations, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.